Incidence of Gastrointestinal Perforation in Users of ACTEMRA® (Tocilizumab), Abatacept and Anti-Tumor Necrosis Factor Alpha Agents First published 23/11/2016 Last updated 01/04/2024 EU PAS number:EUPAS16143 Study Finalised